1. GPCR/G Protein
  2. Prostaglandin Receptor

Prostaglandin Receptor

Prostaglandin receptor, a sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors. There are currently ten known prostaglandin receptors on various cell types. Prostaglandins bind to a subfamily of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are named: DP1-2-DP1, DP2 receptors, EP1-4-EP1, EP2, EP3, EP4 receptors, FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor. The prostaglandins are a group of hormone-like lipid compounds that are derived enzymatically from fatty acids and have important functions in the animalbody. There are currently ten known prostaglandin receptors on various cell types.

Prostaglandin Receptor Related Products (39):

Cat. No. Product Name Effect Purity
  • HY-B0131
    Prostaglandin E1 Agonist >98.0%
    Prostaglandin E1 (Alprostadil) is a prostaglandin, which is used in the treatment of erectile dysfunction and has vasodilatory properties.
  • HY-14870
    NS-304 Agonist 99.97%
    NS-304 is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor).
  • HY-16781
    Grapiprant Antagonist 99.68%
    Grapiprant is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2).
  • HY-18966
    PF-04418948 Antagonist 99.60%
    PF-04418948 is a novel, potent and selective prostaglandin EP2 receptor antagonist with IC50 of 16 nM, displays >2000-fold functional selectivity for the human EP2 receptor over antagonist activity against the human EP1, EP3, EP4, DP1 and CRTH2 receptors.
  • HY-16978
    TG6-10-1 Antagonist 98.64%
    TG6-10-1 is an EP2 antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors.
  • HY-101952
    Prostaglandin E2 Activator >98.0%
    Prostaglandin E2 is a vasodilator isolated from prostate gland secretion, working by binding and activating the prostaglandin E2 receptor.
  • HY-101987
    BW 245C Agonist 99.14%
    BW 245C is a prostanoid DP-receptor (DP1) agonist, used to treat stroke.
  • HY-103088
    E7046 Antagonist 99.46%
    E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities.
  • HY-A0096
    Iloprost Agonist 99.83%
    Iloprost (ZK 36374) is a synthetic analogue of prostacyclin PGI2.
  • HY-B0577
    Latanoprost Agonist
    Latanoprost is a selective agonist for the FP prostanoid receptor, is used as a powerful antiglaucoma agent.
  • HY-16991
    Terutroban Antagonist 99.59%
    Terutroban is a thromboxane/prostaglandin endoperoxide receptor antagonist.
  • HY-12956A
    Dinoprost tromethamine salt Agonist >98.0%
    Dinoprost(Prostaglandin F2α) tromethamine salt is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient.
  • HY-50901
    ONO-AE3-208 Antagonist >98.0%
    ONO-AE3-208 is an EP4 antagonist, and suppresses cell invasion, migration, and metastasis of prostate cancer.
  • HY-B0191
    Bimatoprost Agonist
    Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.
  • HY-16635
    Setipiprant Antagonist 98.14%
    Setipiprant is an orally available, selective CRTH2 antagonist. CRTH2 is a G protein-coupled receptor for PGD2.
  • HY-14899
    Taprenepag Agonist
    CP-544326 is a potent and selective prostaglandin E2 receptor agonist (EC50 = 2.8 nM) .
  • HY-10418
    AH 6809 Antagonist 99.47%
    AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP1, EP2, EP3-III, and DP1 receptors.
  • HY-50175
    Laropiprant Antagonist 99.66%
    Laropiprant is a potent, selective DP1 receptor antagonist with Ki value of 0.57 nM, and exhibits > 1,000 fold selectivity over DP2 receptor (Ki=0.75 μM).
  • HY-16963
    GW627368 Antagonist 99.88%
    GW627368(GW627368X) is a novel, potent and selective competitive antagonist of prostanoid EP4 receptor(Ki= 100 nM) with additional human TP receptor affinity(Ki= 150 nM).
  • HY-14839
    Evatanepag Agonist 98.02%
    Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.